Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × apalutamide × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 44 Prostatic Neoplasms, Castration-Resistant 2 Neoplasm Metastasis 2 Stage II Prostate Adenocarcinoma 1 Small Cell Lung Carcinoma 1 Salivary Gland Neoplasms 1 Prostate Cancer Metastatic Disease 1 Prostate Adenocarcinoma 1 Newly Diagnosed Oligometastatic Prostate Cancer 1 Neoplasms 1 Neoadjuvant Therapy 1 Low Risk Prostate Cancer 1 High Risk Prostate Cancer 1 Hematologic Neoplasms 1 Castration Levels of Testosterone 1 Carcinoma, Small Cell 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Gemcitabine 52 Bevacizumab 52 Cyclophosphamide 49 Docetaxel 42 Carboplatin 40 pembrolizumab 36 Paclitaxel 36 Fluorouracil 36 Cisplatin 35 Radiotherapy 31 Oxaliplatin 31 Capecitabine 29 Irinotecan 28 Dexamethasone 27 Leucovorin 25 Cetuximab 25 Nivolumab 24 Doxorubicin 22 Drug Therapy 21 Erlotinib Hydrochloride 20 Pemetrexed 19 durvalumab 18 trametinib 17 fludarabine 16 atezolizumab 16 Trastuzumab 16 Sunitinib 16 Rituximab 16 Prednisone 16 Sorafenib 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04295447 2024-06-20

ADAM

Universität Münster

Phase 2 Active not recruiting

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡